CoChat
Sign Up
Cited by 1,018Atrial Fibrillation Management and OutcomesCardiovascular and Diving-Related ComplicationsAcute Ischemic Stroke Management

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation: A Randomized Clinical Trial

Reddy, Vivek Y., Sievert, Horst, Halperin, Jonathan, Doshi, Shephal K., Buchbinder, Maurice, Neuzil, Petr, Huber, Kenneth, Whisenant, Brian, Kar, Saibal, Swarup, Vijay, Gordon, Nicole, Holmes, David·2014·JAMA
DOI 10.1001/jama.2014.15192
Open this paper in CoChat — free account

Abstract

IMPORTANCE: While effective in preventing stroke in patients with atrial fibrillation (AF), warfarin is limited by a narrow therapeutic profile, a need for lifelong coagulation monitoring, and multiple drug and diet interactions. OBJECTIVE: To determine whether a local strategy of mechanical left atrial appendage (LAA) closure was noninferior to warfarin. DESIGN, SETTING, AND PARTICIPANTS: PROTECT AF was a multicenter, randomized (2:1), unblinded, Bayesian-designed study conducted at 59 hospitals of 707 patients with nonvalvular AF and at least 1 additional stroke risk factor (CHADS2 score ≥1). Enrollment occurred between February 2005 and June 2008 and included 4-year follow-up through October 2012. Noninferiority required a posterior probability greater than 97.5% and superiority a probability of 95% or greater; the noninferiority margin was a rate ratio of 2.0 comparing event rates between treatment groups. INTERVENTIONS: Left atrial appendage closure with the device (n = 463) or warfarin (n = 244; target international normalized ratio, 2-3). MAIN OUTCOMES AND MEASURES: A composite efficacy end point including stroke, systemic embolism, and cardiovascular/unexplained death, analyzed by intention-to-treat. RESULTS: At a mean (SD) follow-up of 3.8 (1.7) years (2621 patient-years), there were 39 events among 463 patients (8.4%) in the device group for a primary event rate of 2.3 events per 100 patient-years, compared with 34 events among 244 patients (13.9%) for a primary event rate of 3.8 events per 100 patient-years with warfarin (rate ratio, 0.60; 95% credible interval, 0.41-1.05), meeting prespecified criteria for both noninferiority (posterior probability, >99.9%) and superiority (posterior probability, 96.0%). Patients in the device group demonstrated lower rates of both cardiovascular mortality (1.0 events per 100 patient-years for the device group [17/463 patients, 3.7%] vs 2.4 events per 100 patient-years with warfarin [22/244 patients, 9.0%]; hazard ratio [HR], 0.40; 95% CI, 0.21-0.75; P = .005) and all-cause mortality (3.2 events per 100 patient-years for the device group [57/466 patients, 12.3%] vs 4.8 events per 100 patient-years with warfarin [44/244 patients, 18.0%]; HR, 0.66; 95% CI, 0.45-0.98; P = .04). CONCLUSIONS AND RELEVANCE: After 3.8 years of follow-up among patients with nonvalvular AF at elevated risk for stroke, percutaneous LAA closure met criteria for both noninferiority and superiority, compared with warfarin, for preventing the combined outcome of stroke, systemic embolism, and cardiovascular death, as well as superiority for cardiovascular and all-cause mortality. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00129545.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.2014.15192

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

Sorted by citations

Items 701–800 of 1,000

Related

See all

Metadata

Authors
Reddy, V. Y., Sievert, H., Halperin, J., Doshi, S. K., Buchbinder, M., Neuzil, P., Huber, K., Whisenant, B., Kar, S., Swarup, V., Gordon, N., & Holmes, D.
Affiliations
  • Na Homolce Hospital (CZ)
  • Cardiovascular Center Frankfurt (DE)
  • Icahn School of Medicine at Mount Sinai (US)
  • Saint John's Health Center (US)
  • Foundation for Cardiovascular Medicine, La Jolla, California
  • Homolka Hospital, Prague, Czech Republic
  • Saint Luke's Hospital (US)
  • Intermountain Medical Center (US)
  • Cedars-Sinai Medical Center (US)
  • Arizona Heart Rhythm Center, Scottsdale
  • Boston Scientific (United States) (US)
  • Mayo Clinic (US)
Corresponding author
Reddy, Vivek Y.
ORCID
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2014-11-19
Volume
312
Issue
19
Pages
1988
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.2014.15192
OpenAlex
W2112970567
Cited by
1,018
References
25
Citations by year
2026: 73 · 2025: 86 · 2024: 87 · 2023: 102 · 2022: 97 · 2021: 84 · 2020: 75 · 2019: 58 · 2018: 87 · 2017: 104 · 2016: 75 · 2015: 77 · 2014: 6
FWCI
59.90
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cardiovascular and Diving-Related Complications
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords
left atrial appendage closure, warfarin, atrial fibrillation, stroke prevention, systemic embolism, cardiovascular mortality, non-inferiority, non-valvular atrial fibrillation, CHADS2 score, anticoagulation, international normalized ratio, bleeding complications, quality of life, patient satisfaction, patient-reported outcomes
MeSH terms
Aged, Aged, 80 and over, Anticoagulants, Atrial Fibrillation, Bayes Theorem, Cardiovascular Diseases, Embolism, Female, Cardiac Catheterization, Humans, Male, Middle Aged, Risk Factors, Warfarin, Survival Analysis, Treatment Outcome, Prosthesis Implantation, Atrial Appendage, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review